Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

NCT05364424 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05364424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
November 4, 2022
Completion date
October 15, 2025
Enrollment
43 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl)